10 Tips To Know About ADHD Medication Pregnancy
ADHD Medication During Pregnancy and Breastfeeding
Women with ADHD face a difficult decision on whether to keep or stop taking ADHD medication during pregnancy and breast-feeding. There isn't much information on how long-term exposure to these drugs may affect the foetus.
A study recently published in Molecular Psychiatry demonstrates that children exposed to ADHD medication during pregnancy do not develop neurological problems such as impaired hearing or vision, febrile seizures or IQ impairment. The authors acknowledge that more high quality studies are required.
Risk/Benefit Analysis
Pregnant women who use ADHD medications need to balance the benefits of using them against the risks to the fetus. Doctors don't have the necessary data to provide clear recommendations but they can provide information on benefits and risks that can assist pregnant women in making informed choices.
A study published in Molecular Psychiatry concluded that women who were taking ADHD medication during early pregnancy did not have a higher risk of fetal malformations, or structural birth defects. Researchers used a vast, population-based case-control study to determine the prevalence of major structural birth defects in infants born to mothers who had taken stimulants in the early stages of pregnancy and those who had not. Pediatric cardiologists and clinical geneticists examined the cases to ensure correct classification of the cases and to reduce the possibility of bias.
The study of the researchers was not without its limitations. Most important, they were unable to distinguish the effects of the medication from those of the disorder at hand. This makes it difficult for researchers to determine whether the small associations observed among the exposed groups were due to the use of medications, or if they were caused by co-morbidities. In addition the researchers did not look at the long-term outcomes of offspring.
The study did reveal that infants whose mothers took ADHD medications during pregnancy were at slightly higher risk of being admitted to the neonatal intensive care unit (NICU) than infants who whose mothers did not take any medication or stopped their medications before or during pregnancy. This was due to central nervous system disorders, and the higher risk of admission was not found to be influenced by the stimulant medications were used during pregnancy.
Women who were taking stimulant ADHD medications during pregnancy also had a higher risk of having caesarean sections or the baby was not scoring well on the Apgar scale (less than 7). These increases appear to be unrelated to the type of medication taken during pregnancy.
Researchers suggest that the small risks associated with the use ADHD medications in early pregnancies may be offset by the greater benefits to both mother and baby of continuing treatment for the woman’s disorder. Doctors should discuss with their patients about this issue and try to help them develop coping skills that may reduce the impact of her disorder in her daily life and relationships.
Medication Interactions
As more women than ever are being diagnosed with ADHD and treated with medication, the dilemma of whether to keep or stop treatment during pregnancy is one that doctors are having to face. Often, medication adhd adults are made in the absence of solid and reliable evidence either way, so physicians have to weigh their experience from their own experiences, those of other doctors, and what the research suggests about the subject, along with their best judgment for each individual patient.
Particularly, the issue of potential risks to the baby can be a challenge. The research on this issue is based on observation rather than controlled studies, and the results are contradictory. The majority of studies limit their analysis to live births, which can underestimate the severity of teratogenic effects leading to terminations or abortions of pregnancy. The study discussed in this journal club addresses these shortcomings by analyzing data on live and deceased births.
Conclusion: While some studies have revealed a positive correlation between ADHD medications and certain birth defects, other studies have not established a link. Most studies show an unintended, or slightly negative, impact. In the end an accurate risk-benefit analysis must be conducted in every situation.
It isn't easy, but not impossible, for women suffering from ADHD to stop taking their medication. In an article published in Archives of Women's Mental Health, psychologist Jennifer Russell notes that stopping ADHD medication during pregnancy can increase depression, feelings of isolation, and family conflict for patients with ADHD. Furthermore, a loss of medication can affect the ability to complete jobs and drive safely that are crucial aspects of a normal life for many people with ADHD.
She suggests women who are uncertain about whether or not to stop taking medication because of their pregnancy, consider the possibility of educating friends, family members and colleagues about the condition, its impact on daily functioning, and on the benefits of keeping the current treatment regimen. Educating them can also help the woman feel supported as she struggles with her decision. It is important to remember that some medications are able to pass through the placenta therefore, if a patient decides to stop her ADHD medication during pregnancy and breastfeeding, she must be aware of the possibility that traces of the drug could be transferred to the infant.
Birth Defects and Risk of
As the use and misuse of ADHD medication to treat symptoms of attention deficit disorder hyperactivity disorder (ADHD) is increasing, so does concern about the potential adverse effects of the drugs on fetuses. A recent study published in the journal Molecular Psychiatry adds to the existing knowledge about this subject. Utilizing two huge data sets researchers were able to look at more than 4.3 million pregnancies and determine whether the use of stimulant medications increased the risk of birth defects. Researchers discovered that although the overall risk is low, first-trimester ADHD medication use was associated with slightly higher rates of certain heart defects, like ventriculoseptal defects.
The researchers behind the study found no link between early medication use and other congenital anomalies, like facial clefting, or club foot. The findings are in line with previous studies revealing the presence of a small, but significant increase in the risk of developing cardiac malformations in women who started taking ADHD medications prior to the time of the time of pregnancy. This risk increased in the latter half of pregnancy, when many women begin to discontinue their ADHD medications.
Women who were taking ADHD medication in the first trimester were more likely require a caesarean birth and also have an insufficient Apgar after delivery, and have a baby that needed breathing assistance after birth. The researchers of the study were unable to eliminate selection bias because they limited the study to women who did not have any other medical conditions that might have contributed to the findings.
The researchers hope their research will help inform the clinical decisions of doctors who encounter pregnant women. They recommend that, while discussing risks and benefits is important but the decision to stop or maintain treatment should be based on the woman's requirements and the severity of her ADHD symptoms.
The authors caution that, even though stopping the medication is a possibility to look into, it is not advised due to the high prevalence of depression and other mental problems for women who are pregnant or recently gave birth. Research has also shown that women who stop taking their medication will have a difficult transitioning to life without them once the baby is born.
Nursing
It can be a challenge to become a mother. Women suffering from ADHD are often faced with a number of difficulties when they must manage their symptoms, go to doctor appointments, prepare for the birth of a baby and adjust to a new routine. Many women decide to continue taking their ADHD medication during pregnancy.
The risk to a breastfeeding infant is not too high since the majority of stimulant medications is absorbed through breast milk at a low level. The rate of exposure to medication will vary based on the dosage, frequency of administration and time of day. Additionally, different medications enter the infant's system differently through the gastrointestinal tract as well as breast milk, and the effect of this on a newborn infant is not fully understood.
Some doctors may decide to stop stimulant medications during a woman's pregnancy due to the absence of research. This is a difficult choice for the patient, who must balance the benefits of keeping her medication against the potential risks to the fetus. Until more information becomes available, doctors can inquire about pregnant patients whether they have an background of ADHD or if they intend to take medication during the perinatal stage.
A increasing number of studies have shown that the majority of women are able to safely continue taking their ADHD medication while they are pregnant and nursing. In response, an increasing number of patients are choosing to do this. They have found through consultation with their doctor that the benefits of continuing their current medication far outweigh any potential risks.
Women with ADHD who plan to breastfeed should seek advice from an expert psychiatrist prior to becoming pregnant. They should discuss their medication with their doctor and discuss the advantages and disadvantages of continued treatment, including non-pharmacological management strategies. Psychoeducation should also be provided to help women with ADHD understand their symptoms and the root cause Learn about the available treatment options and reinforce existing strategies for managing. This should be a multidisciplinary process with the GPs, obstetricians, and psychiatry. Pregnancy counseling should include discussion of a treatment plan for the mother and child, and monitoring for signs of deterioration and, if necessary adjustments to the medication regimen.